This suggestion is based on studies showing that plasma ACE2 activity was increased in COVID-19 patients treated with a pharmacological ACE inhibitor(52) and that ACE inhibitors increased cardiac ACE2 gene transcription in Lewis rats(53). This evidence concerns the gene ACE and COVID-19.